Bio-Path Holdings, Inc. (BPTH)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.2000 |
| Open | 3.2300 |
| Bid | 3.1300 x 800 |
| Ask | 3.2500 x 1100 |
| Day's Range | 3.1233 - 3.2955 |
| 52 Week Range | 2.6800 - 8.6200 |
| Volume | |
| Avg. Volume | 67,456 |
| Market Cap | 22.411M |
| Beta (5Y Monthly) | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4760 |
| Earnings Date | Mar 08, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Bio-Path Holdings Reports First Quarter 2022 Financial Results
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2022 and provided an update on recent corporate developments. “Throughout the first quarter, we continued to advance our missi
- Simply Wall St.
We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, May 17, 2022 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2022 and to provide a business overview. To access the live conference ca
